Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BOHS Announces Eleventh Inhaled Particles Symposium

Published: Monday, March 04, 2013
Last Updated: Sunday, March 03, 2013
Bookmark and Share
Symposium will be held in the city of Nottingham from 23 to 25 September 2013.

The British Occupational Hygiene Society (BOHS) has announced its latest Inhaled Particles symposium, the eleventh in a long line of highly successful and prestigious conferences, to be held in the city of Nottingham from 23 to 25 September 2013.

The first Inhaled Particles symposium was held at Oxford University in 1960, making the meetings the oldest ongoing international symposium series on the health effects of particles.

Over the intervening fifty years, the ten Inhaled Particles meetings have witnessed all of the key developments in occupational and public health associated with airborne particles.

In particular, the Inhaled Particles symposia have been distinguished by an integrative approach to the science of particle-mediated lung disease, involving exposure scientists, epidemiologists, toxicologists and others concerned about the harm caused by inhaling particles.

The early symposia were important in helping establish standards for dust control in coalmines in the UK and other countries, reducing the incidence of pneumoconiosis among miners.

By the 1980s and 1990s, the main emphasis had shifted to fibres, including asbestos.

Inhaled Particles XI (IPXI), to be held at Nottingham Conference Centre, at Nottingham Trent University, will take a multi-disciplinary approach, addressing topics within:
• exposure, for example controls, instrumentation and measurement
• hazards, including deposition, clearance, particokinetics, toxicology, and mechanisms of disease
• risk assessment, for example epidemiology, health impacts and links with policy.

BOHS is inviting all researchers who work on exposure, metrology, epidemiology, toxicology and risk assessment in particle-associated diseases to attend the latest meeting.

In addition, BOHS continues to invite authors to submit abstracts for oral or poster presentations. All abstracts must be submitted no later than 8 April 2013. Authors will be notified by 10 May 2013.

Key speakers will include the following.
• Dr Michael Attfield is a senior epidemiologist and expert on coal miner health. He acted as co-director in a major project to examine the relationship between lung cancer and exposure to diesel exhaust. The findings of this project led to the determination by the International Agency for Research on Cancer (IARC) that there was sufficient evidence that diesel exhaust particulate was a human carcinogen.
• Dr Derk Brouwer is a senior scientist in exposure assessment with the Dutch Organization for Applied Scientific Research TNO in the Netherlands. He is active in a wide range of international projects on assessment of worker exposure to nanoparticles. In particular his research focuses on measurement strategies and exposure modeling issues.
• Dr Vince Castranova is the Chief of the Pathology and Physiology Research Branch at the National Institute for Occupational Safety and Health (NIOSH) in Morgantown, West Virginia. His research interests have been concentrated in pulmonary toxicology and occupational lung disease. He has been coordinator of the Nanotoxicology Program in NIOSH since its inception in 2005.
• Dave Litton, a Senior Research Physicist at NIOSH in Pittsburgh, Pennsylvania, is an expert in fire detection, flame spectroscopy and optical diagnostics as well as in the measurement of combustion-generated particulate matter. For the past 12 to 15 years his research has been divided between managing combustion projects related to fire and explosion safety, and new approaches to atmospheric dusts and aerosols.

Commenting on the plans for September 2013, Professor Ken Donaldson, Chair of the IPXI Scientific Committee, said “IPXI will seek to continue its fine tradition of over fifty years, bringing together leading researchers on the adverse effects of particles on the lungs and extra-pulmonary target tissues to showcase cutting edge research and debate solutions to the challenges faced within particle research and risk assessment”.

Further information about the event, including booking forms, can be accessed at www.inhaledparticles.org/. Delegates who book before 1 July 2013 will receive an “early bird” discounted rate of £540.00.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
Testing Nanoparticle Drug Delivery in Dogs
Scientists have tested a nanoparticle drug delivery against bone cancer in dogs with promising results.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Development in Preventing Macular Degeneration
Following macular degeneration insight, promising drugs to prevent vision loss have been identified.
Improving Tumour Therapy with Nanoparticles
UHN nanoparticle called PEARLs is a promising utilisation of photo-thermal therapy for cancer treatment.
New Antidepressant Treatment Discovered
Scientists have demonstrated how gene therapy could lead to new treatments for depression.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!